The Government of India has restricted the manufacture, sale, and distribution of all fixed dose combination formulations containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride unless a mandatory warning is displayed stating that the product should not be used in children below four years of age. The decision is based on safety concerns and recommendations from expert committees and the Drugs Technical Advisory Board.

